India Pharma Outlook Team | Tuesday, 13 October 2026
New data confirm that ReadyFlow delivers consistent results whether patients receive the injection in the arm or the thigh.
MannKind Corporation presents evidence at the Heart Failure Society of America Annual Scientific Meeting showing that Furoscix ReadyFlow produces nearly identical drug exposure and diuretic effects at both sites.
The findings give clinicians greater flexibility when treating fluid overload in heart failure and chronic kidney disease.
ReadyFlow already stands as the first and only autoinjector that matches intravenous furosemide performance, and these results further strengthen its role in outpatient care.
Healthcare teams can now choose the most convenient injection site without sacrificing therapeutic impact.
A randomized crossover study compared subcutaneous furosemide delivered by the ReadyFlow autoinjector in the thigh and the upper arm against intravenous administration.
ReadyFlow met the pre-determined bioequivalence criteria for overall drug exposure at both locations. Relative bioavailability reached 91.3 percent in the thigh and 92.7 percent in the upper arm.
Urine output and urinary sodium excretion stayed similar across all three treatments. Patients generally tolerated the injections well. These results directly support the use of either the arm or the thigh while preserving consistent therapeutic performance.
Key takeaways from the injection-site study include:
Also Read: How Can India Pharma Bridge the Gap Between Innovation and Access
Another analysis placed ReadyFlow side by side with the earlier Furoscix On-body Infusor. Both subcutaneous formulations achieved bioequivalence to intravenous furosemide and produced comparable diuretic and natriuretic responses.
The autoinjector completes the full 80 mg/mL dose in under 10 seconds, offering a clear practical advantage for busy clinics and home settings.
Cross-study comparisons require caution because the trials enrolled separate populations, yet the data still demonstrate that both delivery methods provide IV-equivalent outpatient diuresis. The rapid administration profile of ReadyFlow adds meaningful convenience without compromising effect.
The U.S. Food and Drug Administration approved Furoscix ReadyFlow in July 2026 for the treatment of fluid overload linked to heart failure or chronic kidney disease in adults. The device delivers subcutaneous furosemide with intravenous-equivalent exposure and diuretic effect.
Dr. Ajay Ahuja, Chief Medical Officer of MannKind, notes that these data expand the growing body of evidence supporting ReadyFlow as an important treatment option. Healthcare providers can manage worsening congestion earlier and outside the hospital.
Michael Castagna, Chief Executive Officer, emphasizes that patients with heart failure and chronic kidney disease often face recurrent fluid overload that leads to emergency visits and hospitalizations. ReadyFlow now gives clinicians a fast, flexible tool to intervene sooner.
Practical advantages highlighted by the new data:
These presentations at HFSA 2026 reinforce ReadyFlow’s position as a practical advance for managing edema. Clinicians gain confidence as the autoinjector works equally well in the arm or the thigh, giving them more options to keep patients out of the hospital while delivering reliable diuretic therapy.
.jpg)
